Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Jürgen Hanisch

Showing results (1-10 of 4) with videos related to

Pageof 1
Sort By:
The Annals of Pharmacotherapy|February 3, 2004
Complementary medicine prescription patterns in GermanyBerthold Schneider, Jürgen Hanisch, Michael Weiser
Inflammation & Allergy Drug Targets|April 29, 2014
Targeting inflammation in cancer-related-fatigue: a rationale for mistletoe therapy as supportive care in colorectal cancer patientsPaul R Bock, Jürgen Hanisch, Harald Matthes, et al.
Arzneimittel-Forschung|February 25, 2005
Safety and efficacy of the long-term adjuvant treatment of primary intermediate- to high-risk malignant melanoma (UICC/AJCC stage II and III) with a standardized fermented European mistletoe (Viscum album L.) extract. Results from a multicenter, comparative, epidemiological cohort study in Germany and SwitzerlandMatthias Augustin, Paul R Bock, Jürgen Hanisch, et al.
Arzneimittel-Forschung|October 6, 2004
[Efficacy and safety of long-term complementary treatment with standardized European mistletoe extract (Viscum album L.) in addition to the conventional adjuvant oncologic therapy in patients with primary non-metastasized mammary carcinoma. Results of a multi-center, comparative, epidemiological cohort study in Germany and Switzerland]Paul R Bock, Walter E Friedel, Jürgen Hanisch, et al.
Pageof 1

Showing results (1-10 of 4) with videos related to

Sort By:
Pageof 1
The Annals of Pharmacotherapy|February 3, 2004
Complementary medicine prescription patterns in GermanyBerthold Schneider, Jürgen Hanisch, Michael Weiser
Inflammation & Allergy Drug Targets|April 29, 2014
Targeting inflammation in cancer-related-fatigue: a rationale for mistletoe therapy as supportive care in colorectal cancer patientsPaul R Bock, Jürgen Hanisch, Harald Matthes, et al.
Arzneimittel-Forschung|February 25, 2005
Safety and efficacy of the long-term adjuvant treatment of primary intermediate- to high-risk malignant melanoma (UICC/AJCC stage II and III) with a standardized fermented European mistletoe (Viscum album L.) extract. Results from a multicenter, comparative, epidemiological cohort study in Germany and SwitzerlandMatthias Augustin, Paul R Bock, Jürgen Hanisch, et al.
Arzneimittel-Forschung|October 6, 2004
[Efficacy and safety of long-term complementary treatment with standardized European mistletoe extract (Viscum album L.) in addition to the conventional adjuvant oncologic therapy in patients with primary non-metastasized mammary carcinoma. Results of a multi-center, comparative, epidemiological cohort study in Germany and Switzerland]Paul R Bock, Walter E Friedel, Jürgen Hanisch, et al.
Pageof 1